Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Forge Biologics

Forge Biologics

Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality.

Forge Biologics, based in Grove City, Ohio, manufactures gene therapies for rare diseases. It is primarily focused on a gene therapy solution for Krabb Disease, described as a "pediatric leukodystrophy affecting about 1 in 100,000 people in the U.S."

The company is developed FBX-101 to treat Krabb disease. It has been shown to "dramatically improve the lifespan of trated animals."

Forge Biologics plans to build a 175,000 sq. ft office and production facility that is cGMP compliant in the E.U. and U.S.

Timeline

June 3, 2021
Forge Biologics expands gene therapy leadership team with appointment of John Maslowski as Chief Commercial Officer.
April 29, 2021
Forge Biologics raises a $120,000,000 series B round.
July 21, 2020
Forge Biologics raises a $40,000,000 series A round from Drive Capital and Perceptive Advisors.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
BioSpace
June 3, 2021
BioSpace
Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), announced today the appointment of John Maslowski to the newly created role of Chief Commercial Officer.
Chardan
April 29, 2021
www.prnewswire.com:443
/PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as exclusive placement agent in the successful closing of $120 million Series...
Alex Keown
April 29, 2021
BioSpace
Ohio-based Forge Biologics secured $120 million in a Series B financing round to support the clinical development of its gene therapy program for rare diseases, including the typically fatal Krabbe disease.
FinSMEs
April 29, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
April 29, 2021
BioSpace
Forge Biologics Announces Closing of $120 Million Series B Financing - read this article along with other careers information, tips and advice on BioSpace
SHOW MORE
Golden logo
By using this site, you agree to our Terms & Conditions.